France renews CIR tax credits for ARTES R&D services

Langenfeld, Germany: –Specialist in microbial process development and technology transfer for the pharmaceutical industry, ARTES Biotechnology GmbH (ARTES) have announced the French Ministry of Higher Education and Research (MESR) had renewed approval for ‘Crédit d’Impôt Recherche’ (CIR) for a further three-years.

The CIR research tax accreditation gives French companies the ability to claim tax relief on 30% of all generated costs outsourced to ARTES’ R&D services.

Validated R&D provider

“We are pleased to receive this accreditation from the French Ministry, further confirming our approval as a validated and reliable R&D provider,” said ARTES Managing Director, Dr. Michael Piontek.

“It allows our customers in France to benefit from tax relief of their R&D expenses committed to us and it will help us to tie up our relationships with our present clients in France and to install new collaborations,” said Dr. Piontek.

Cell line engineering

ARTES Biotechnology is globally active as R&D company specialized in developing production processes for biopharmaceuticals and vaccines.

The company operates worldwide from its 850m² S1 facilities in Langenfeld, from where it also offers cell line engineering based on yeast (Hansenula polymorpha) and bacterial (E. coli) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.

For vaccine development, ARTES provides amongst others its well-proven and patented virus-like-particle (VLP) antigen presentation platform METAVAX^® that can be combined with ARTES’ proprietary yeast expression technology. These platforms combined engineer excellent cell lines and processes for effective, safe and affordable vaccines.

About ARTES Biotechnology

ARTES Biotechnology is a pharmaceutical contract research & development organization that provides cell line and process development for and manufacturing of bio-pharmaceutical products. The company is a well-established partner for many of the biggest names in the industry, with more than 20 years of business experience, a track record of products developed for and marketed by clients, as well as safe, reliable and highly competitive microbial production platforms.

ARTES specializes in recombinant cell line, process and vaccine development from microbial expression systems, marketing the unique METAVAX^® (dHepB-eVLP) and SplitCore (HepBcVLP) technology in combination with yeast and E. coli expression.

ARTES operates worldwide from its 850m² S1 facilities in Langenfeld, from where it offers cell line engineering based on yeast (Hansenula polymorpha, syn. Pichia angusta; Saccharomyces cerevisiae) and bacterial (E. coli) expression platforms, lab scale up- and downstream process development, supply of non-GMP bulk material (API) for activity and toxicity tests and technology transfer to cGMP facilities and scale-up support.

More information at www.artes-biotechnology.com